Healthcare Deals: Big Pharma, Megamergers & IPOs
- 3.10.2015 | 7:00 PM - 8:00 PM
Pharmaceutical and biotechnology companies had a blockbuster year in 2014, with a record number of IPOs and continuing pace of mergers and acquisitions. Starting out 2015 in a similar vein, large pharma companies such as Shire and Pfizer began purchasing companies in the space. With the IPO market facing macroeconomic headwinds, could we see more acquisitions of smaller emerging biotechnology companies by larger players? Is 2015 the year where we will see megamergers that have failed to occur—such as Pfizer and AstraZeneca last year? Could private equity take interest in more early stage pharmaceutical companies? What could this mean for M&A activity in the space for the coming year?
Register to watch the live video roundtable discussion of how cancer drugs and orphan drugs are often attractive, but what other areas will be hot in 2015? Will we see a larger pharmaceutical megamerger? Or will smaller companies continue to go at it on their own? What will this mean for early-stage biopharma? And who will be the big consolidators in the space?